Gut · 2008 · 96 citations · 34 references
Life SciencesCell BiologyOncologyApoptosisCell SignalingSignal TransductionApoptosis RegulationApoptosis ResistanceCancer Cell SignalingOncogenic Signaling PathwaysPancreatic CancerSignal Transduction In CancerAnti-apoptotic AgentsAnti-apoptotic ModulationAnti-apoptotic ProteinsCancer Cell Survival SignalingProtein Expression LevelsReal-time Polymerase Chain Reaction (Pcr)Tissue XenotransplantationWestern Blotting
BACKGROUND: Pancreatic ductal adenocarcinomas (PDACs) are highly resistant to treatment due to changes in various signalling pathways. CK1 isoforms play important regulatory roles in these pathways. AIMS: We analysed the expression levels of CK1 delta and epsilon (CK1delta/in) in pancreatic tumour cells in order to validate the effects of CK1 inhibition by 3-[2,4,6-(trimethoxyphenyl)methylidenyl]-indolin-2-one (IC261) on their proliferation and sensitivity to anti-CD95 and gemcitabine. METHODS: CK1delta/in expression levels were investigated by using western blotting and immunohistochemistry. Cell death was analysed by FACS analysis. Gene expression was assessed by real-time PCR and western blotting. The putative anti-tumoral effects of IC261 were tested in vivo in a subcutaneous mouse xenotransplantation model for pancreatic cancer. RESULTS: We found that CK1delta/in are highly expressed in pancreatic tumour cell lines and in higher graded PDACs. Inhibition of CK1delta/in by IC261 reduced pancreatic tumour cell growth in vitro and in vivo. Moreover, IC261 decreased the expression levels of several anti-apoptotic proteins and sensitised cells to CD95-mediated apoptosis. However, IC261 did not enhance gemcitabine-mediated cell death either in vitro or in vivo. CONCLUSIONS: Targeting CK1 isoforms by IC261 influences both pancreatic tumour cell growth and apoptosis sensitivity in vitro and the growth of induced tumours in vivo, thus providing a promising new strategy for the treatment of pancreatic tumours.
34
Two CD95 (APO‐1/Fas) signaling pathways
Carsten Scaffidi · The EMBO Journal · 1998 · 3K citations · Full text
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Concepción Almoguera, Darryl Shibata, Kathleen Forrester et al. · Cell · 1988 · 2.1K citations
Tumor-suppressive pathways in pancreatic carcinoma.
Ester Rozenblum, Mieke Schutte, Michael Goggins et al. · PubMed · 1997 · 699 citations